ECSP024365A - Moleculas mutantes solubles ctla4 y sus aplicaciones - Google Patents
Moleculas mutantes solubles ctla4 y sus aplicacionesInfo
- Publication number
- ECSP024365A ECSP024365A EC2002004365A ECSP024365A ECSP024365A EC SP024365 A ECSP024365 A EC SP024365A EC 2002004365 A EC2002004365 A EC 2002004365A EC SP024365 A ECSP024365 A EC SP024365A EC SP024365 A ECSP024365 A EC SP024365A
- Authority
- EC
- Ecuador
- Prior art keywords
- ctla4
- mutant molecules
- applications
- amino acid
- molecules
- Prior art date
Links
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 title abstract 6
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 title abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 108010035053 B7-1 Antigen Proteins 0.000 abstract 1
- 102000038504 B7-1 Antigen Human genes 0.000 abstract 1
- 102000007697 B7-2 Antigen Human genes 0.000 abstract 1
- 108010021800 B7-2 Antigen Proteins 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57992700A | 2000-05-26 | 2000-05-26 | |
| US21406500P | 2000-06-26 | 2000-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP024365A true ECSP024365A (es) | 2003-03-31 |
Family
ID=26908652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2002004365A ECSP024365A (es) | 2000-05-26 | 2002-11-26 | Moleculas mutantes solubles ctla4 y sus aplicaciones |
Country Status (41)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| HU226847B1 (en) * | 2000-07-03 | 2009-12-28 | Bristol Myers Squibb Co | Use of soluble ctla4 molecules for treating of rheumatoid arthritis |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| JP4837880B2 (ja) | 2001-05-23 | 2011-12-14 | ブリストル−マイヤーズ スクイブ カンパニー | 可溶性ｃｔｌａ４突然変異体分子を使って同種異系島移植片を保護する方法 |
| AU2003243152A1 (en) * | 2002-04-19 | 2003-11-03 | Bristol-Myers Squibb Company | Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
| DE10232697A1 (de) * | 2002-07-15 | 2004-02-05 | Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin | Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen |
| US7541164B2 (en) * | 2002-12-23 | 2009-06-02 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| BR0316882A (pt) * | 2002-12-23 | 2005-10-25 | Bristol Myers Squibb Co | Melhora na qualidade de produtos em processos de cultura de células de mamìferos para a produção de proteìnas |
| AU2003299971A1 (en) | 2002-12-30 | 2004-07-29 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| WO2005044188A2 (en) | 2003-10-27 | 2005-05-19 | Amgen Inc. | Compositions and methods to modulate an immune response to an immunogenic therapeutic agent |
| PT1969007E (pt) | 2005-12-20 | 2013-12-10 | Bristol Myers Squibb Co | Composições e métodos para a produção de uma composição |
| AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| US7510844B2 (en) | 2006-01-24 | 2009-03-31 | Bristol-Myers Squibb Company | CD86 and CD80 receptor competition assays |
| WO2008005290A2 (en) | 2006-06-29 | 2008-01-10 | The Trustees Of Columbia University In The City Of New York | Methods for testing anti-thrombotic agents |
| GB0620934D0 (en) | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
| CN103709249B (zh) | 2006-12-20 | 2016-02-24 | Mmr全球公司 | 抗体及其制备和使用方法 |
| EP2612868B1 (en) | 2007-11-01 | 2018-08-15 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
| KR20180105731A (ko) * | 2008-10-02 | 2018-09-28 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Ｃｄ86 길항제 다중-표적 결합 단백질 |
| US9540426B2 (en) | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| WO2011113019A2 (en) * | 2010-03-12 | 2011-09-15 | Abbott Biotherapeutics Corp. | Ctla4 proteins and their uses |
| CN103534345A (zh) | 2011-02-23 | 2014-01-22 | 安姆根有限公司 | 用于uvc暴射的细胞培养基及其相关方法 |
| WO2013010537A1 (en) | 2011-07-20 | 2013-01-24 | Aarhus Universitet | Method of treating morphea |
| US9758566B2 (en) | 2012-03-29 | 2017-09-12 | The General Hospital Corporation | Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4) |
| ES2777778T3 (es) | 2012-05-11 | 2020-08-06 | Medimmune Ltd | Variantes de CTLA-4 |
| US8735359B2 (en) | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
| CN104519900A (zh) * | 2012-06-27 | 2015-04-15 | 欧尔本生物科技有限责任公司 | 用于治疗糖尿病的ctla4融合蛋白 |
| US20140112958A1 (en) | 2012-10-24 | 2014-04-24 | Mwm Biomodels Gmbh | Pancreatic islets of transgenic LEA29Y animals for treating diabetes |
| CN104740608A (zh) * | 2013-12-30 | 2015-07-01 | 上海中信国健药业股份有限公司 | 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途 |
| SG11201605640UA (en) | 2014-01-13 | 2016-08-30 | Amgen Inc | Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins |
| GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
| SI3926051T1 (sl) | 2014-06-04 | 2024-06-28 | Amgen Inc. | Postopki zbiranja celičnih kultur sesalcev |
| ES2784503T3 (es) | 2014-12-01 | 2020-09-28 | Amgen Inc | Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína |
| WO2016130734A1 (en) | 2015-02-11 | 2016-08-18 | Bristol-Myers Squibb Company | Use of phenolic antioxidants in cell culture for the production of proteins |
| CA2982246A1 (en) | 2015-04-17 | 2016-10-20 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| EP3702470A3 (en) | 2015-09-09 | 2020-10-07 | The Trustees of Columbia University in the City of New York | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease |
| CN108350416A (zh) | 2015-11-09 | 2018-07-31 | 百时美施贵宝公司 | 操纵在cho细胞中产生的多肽的品质属性的方法 |
| CN109715210B (zh) * | 2016-09-19 | 2023-05-30 | 昂科医药 | Cd80和cd86结合蛋白组合物及其用途 |
| CN107987153A (zh) * | 2016-10-27 | 2018-05-04 | 广东香雪精准医疗技术有限公司 | 高亲和力的可溶性pd-1分子 |
| WO2018195402A1 (en) | 2017-04-20 | 2018-10-25 | Egenesis, Inc. | Methods for generating genetically modified animals |
| CN111801347A (zh) | 2017-10-10 | 2020-10-20 | 高山免疫科学股份有限公司 | Ctla-4变体免疫调节蛋白和其用途 |
| CA3087149A1 (en) | 2018-01-03 | 2019-07-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| CN109453383A (zh) * | 2018-11-12 | 2019-03-12 | 陈慧慧 | 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用 |
| CA3152665A1 (en) | 2019-08-27 | 2021-03-04 | Tonix Pharma Limited | Modified tff2 polypeptides |
| CN114206907A (zh) | 2019-12-06 | 2022-03-18 | 瑞泽恩制药公司 | 抗vegf蛋白组合物及其制备方法 |
| US12103960B2 (en) | 2020-05-08 | 2024-10-01 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| CA3184812A1 (en) | 2020-06-18 | 2021-12-23 | Regeneron Pharmaceuticals, Inc. | Heavy peptide approach to accurately measure unprocessed c-terminal lysine |
| EP4189056A1 (en) | 2020-07-28 | 2023-06-07 | Seagen Inc. | Methods and systems for producing polypeptides |
| EP4448022A2 (en) | 2021-12-16 | 2024-10-23 | Bristol-Myers Squibb Company | Detergent for viral inactivation |
| AU2023229164A1 (en) | 2022-03-02 | 2024-09-12 | Regeneron Pharmaceuticals, Inc. | Cell culture methods for antibody production |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| ES2123001T5 (es) * | 1991-06-27 | 2009-04-16 | Bristol-Myers Squibb Company | Receptor ctl4a, proteinas de fusion que lo contienen y sus usos. |
| ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
| JP3521382B2 (ja) * | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| GB9809280D0 (en) * | 1998-04-30 | 1998-07-01 | Rpms Technology Ltd | Immunosupression |
| AU1102000A (en) * | 1998-10-07 | 2000-04-26 | Millennium Pharmaceuticals, Inc. | Novel th2-specific molecules and uses thereof |
| HU226847B1 (en) * | 2000-07-03 | 2009-12-28 | Bristol Myers Squibb Co | Use of soluble ctla4 molecules for treating of rheumatoid arthritis |
-
2001
- 2001-05-23 PE PE2001000465A patent/PE20011338A1/es active IP Right Grant
- 2001-05-23 TW TW097137809A patent/TWI319405B/zh not_active IP Right Cessation
- 2001-05-23 AT AT01937764T patent/ATE271066T1/de active
- 2001-05-23 IL IL152315A patent/IL152315A/en active Protection Beyond IP Right Term
- 2001-05-23 SK SK1570-2002A patent/SK288131B6/sk not_active IP Right Cessation
- 2001-05-23 AU AU2001263466A patent/AU2001263466C1/en active Active
- 2001-05-23 DE DE60104282T patent/DE60104282T2/de not_active Expired - Lifetime
- 2001-05-23 TR TR2004/02703T patent/TR200402703T4/xx unknown
- 2001-05-23 UY UY26723A patent/UY26723A1/es not_active IP Right Cessation
- 2001-05-23 MY MYPI20012427A patent/MY136113A/en unknown
- 2001-05-23 EG EG20010548A patent/EG24459A/xx active
- 2001-05-23 EP EP04008908.8A patent/EP1536234B1/en not_active Expired - Lifetime
- 2001-05-23 UA UA20021210563A patent/UA87432C2/uk unknown
- 2001-05-23 KR KR1020077017691A patent/KR100889887B1/ko not_active Expired - Lifetime
- 2001-05-23 GE GE4987A patent/GEP20053658B/en unknown
- 2001-05-23 BR BRPI0111191 patent/BRPI0111191B8/pt not_active IP Right Cessation
- 2001-05-23 ES ES01937764T patent/ES2225549T3/es not_active Expired - Lifetime
- 2001-05-23 PL PL366231A patent/PL206267B1/pl unknown
- 2001-05-23 MX MXPA02011534A patent/MXPA02011534A/es active IP Right Grant
- 2001-05-23 WO PCT/US2001/017139 patent/WO2001092337A2/en not_active Application Discontinuation
- 2001-05-23 CN CNA2007100840790A patent/CN101255192A/zh active Pending
- 2001-05-23 CZ CZ2002-3892A patent/CZ304451B6/cs unknown
- 2001-05-23 DK DK01937764T patent/DK1248802T3/da active
- 2001-05-23 AR ARP010102449A patent/AR031699A1/es active IP Right Grant
- 2001-05-23 EE EEP201100050A patent/EE05557B1/xx unknown
- 2001-05-23 AU AU6346601A patent/AU6346601A/xx active Pending
- 2001-05-23 RU RU2002131588/13A patent/RU2283847C2/ru active Protection Beyond IP Right Term
- 2001-05-23 PT PT01937764T patent/PT1248802E/pt unknown
- 2001-05-23 JP JP2002500948A patent/JP4328525B2/ja not_active Expired - Lifetime
- 2001-05-23 HK HK03100239.8A patent/HK1048126B/en not_active IP Right Cessation
- 2001-05-23 EP EP15197082.9A patent/EP3029062A1/en not_active Withdrawn
- 2001-05-23 TW TW090112431A patent/TWI314933B/zh not_active IP Right Cessation
- 2001-05-23 EE EEP200200659A patent/EE05458B1/xx active Protection Beyond IP Right Term
- 2001-05-23 CN CNB018101453A patent/CN1309735C/zh not_active Expired - Lifetime
- 2001-05-23 CA CA002409748A patent/CA2409748C/en not_active Expired - Lifetime
- 2001-05-23 KR KR1020027015946A patent/KR100895134B1/ko not_active Expired - Lifetime
- 2001-05-23 EP EP01937764A patent/EP1248802B9/en not_active Expired - Lifetime
- 2001-05-23 HU HU0302201A patent/HU228137B1/hu active Protection Beyond IP Right Term
- 2001-05-23 ES ES04008908T patent/ES2571852T3/es not_active Expired - Lifetime
- 2001-05-23 SI SI200130186T patent/SI1248802T1/xx unknown
-
2002
- 2002-11-04 ZA ZA200208944A patent/ZA200208944B/en unknown
- 2002-11-13 LT LT2002114A patent/LT5133B/lt not_active IP Right Cessation
- 2002-11-25 NO NO20025656A patent/NO330797B1/no not_active IP Right Cessation
- 2002-11-26 EC EC2002004365A patent/ECSP024365A/es unknown
- 2002-12-19 LV LVP-02-214A patent/LV12994B/en unknown
-
2011
- 2011-11-10 BE BE2011C041C patent/BE2011C041I2/fr unknown
- 2011-11-16 LU LU91902C patent/LU91902I2/fr unknown
- 2011-12-05 DE DE201112100063 patent/DE122011100063I1/de active Pending
- 2011-12-07 FR FR11C0053C patent/FR11C0053I2/fr active Active
- 2011-12-12 CY CY2011019C patent/CY2011019I2/el unknown
- 2011-12-15 NO NO2011027C patent/NO2011027I1/no not_active IP Right Cessation
-
2013
- 2013-04-12 HU HUS1300012C patent/HUS1300012I1/hu unknown
-
2016
- 2016-06-10 CY CY20161100511T patent/CY1117625T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP024365A (es) | Moleculas mutantes solubles ctla4 y sus aplicaciones | |
| CY1106532T1 (el) | Ετερολογος εκφραση των πρωτεϊνων της neisseria | |
| ATE376026T1 (de) | Klebstoffzusammensetzungen mit selbstorganisierenden molekülen, klebstoffe, gegenstände und verfahren | |
| CY1119291T1 (el) | Πολυσθενη αντισωματα και χρησεις για αυτα | |
| DE602004009764D1 (de) | Pha-klebstoffe | |
| DE60236861D1 (de) | Kombinatorische bibliotheken von monomerdomänen | |
| ATE304583T1 (de) | Klebstoffzusammensetzungen aus pflanzlichem protein | |
| CY1105194T1 (el) | Φωσφονικα παραγωγα γλυκοπεπτιδιων | |
| DK1171417T3 (da) | Fremgangsmåde til fremstilling af 3-aryloxy-3-arylpropylaminer og mellemprodukter deraf | |
| CY1114584T1 (el) | Ανασυνδυασμενα εμβολια και χρηση αυτων | |
| CY1107759T1 (el) | Λυοφιλισμενη συνταγοποιηση που περιλαμβανει ολανζαπινη | |
| NO20044039L (no) | Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider. | |
| ATE509949T1 (de) | Metastasisch spezifische peptide und ihre diagnostischen und therapeutischen anwendungen | |
| WO2003025119A3 (en) | Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies | |
| NO20031860D0 (no) | Kahalaolid F | |
| PA8508301A1 (es) | Inhibidores de la proteina c del procolageno | |
| DE60324799D1 (de) | Em material bestehende schuppen | |
| ATE476177T1 (de) | Orale zubereitungen enthaltend cladribin | |
| CY1110718T1 (el) | Ανοσογονες λιποσωμικες συνθεσεις | |
| MXPA05013268A (es) | Composiciones de poliacetal y de polivinilbutiral y mezclas que tienen propiedades superficiales mejoradas y articulos elaborados a partir de estas. | |
| ATE315380T1 (de) | Epothilon zusammensetzungen | |
| DE602004032235D1 (de) | Dna-vektoren | |
| CY1110139T1 (el) | Γλυκοπεπτιδικα αντιβιοτικα | |
| BR0116614A (pt) | Composições de polìmero biodegradáveis de resposta à água e método de fabricação das mesmas | |
| FI20000219A7 (fi) | Antistaattinen biohajoava muovikalvo ja menetelmä sen valmistamiseksi |